AI-generated analysis. Always verify with the original filing.
Ultragenyx Pharmaceutical Inc. issued a press release on March 12, 2026, announcing positive results from its Phase 3 Enh3ance study. This disclosure under Item 8.01 represents a significant clinical milestone for the Company.